as 07-26-2024 4:00pm EST
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Founded: | 1965 | Country: | United States |
Employees: | N/A | City: | BRISBANE |
Market Cap: | 5.2M | IPO Year: | N/A |
Target Price: | $105.00 | AVG Volume (30 days): | 51.5K |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.98 | EPS Growth: | N/A |
52 Week Low/High: | $2.60 - $10.66 | Next Earning Date: | 08-09-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
GTBP Breaking Stock News: Dive into GTBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Simply Wall St.
2 months ago
Motley Fool
2 months ago
Motley Fool
2 months ago
Simply Wall St.
2 months ago
Motley Fool
2 months ago
AFP
2 months ago
Motley Fool
2 months ago
The information presented on this page, "GTBP GT Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.